Trial Profile
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese T2DM Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive: A Multicenter, Randomized, Open Label, Prospective Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Acarbose; Aspirin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACADEMIC
- Sponsors Sanofi; Sanofi China Investment
- 01 Jun 2022 Results published in the Diabetes, Obesity and Metabolism
- 20 Jan 2021 Status changed from active, no longer recruiting to completed.
- 16 Nov 2020 Planned End Date changed from 1 Feb 2021 to 1 Dec 2020.